Type II anti-CD20 monoclonal antibody that depletes CD20+ B cells via antibody-dependent cellular cytotoxicity, complement-mediated cytotoxicity, and direct cell death.
Glycoengineered type II anti-CD20 humanized IgG1 monoclonal antibody that binds CD20 on B cells and depletes them via enhanced antibody-dependent cellular cytotoxicity (increased FcγRIIIa affinity), complement-dependent cytotoxicity, and direct caspase-independent apoptosis.
NO
INDIRECT
Obinutuzumab binds CD20 on B cells; its Fc engages FcγRIIIa on NK cells/monocytes to activate ADCC/phagocytosis that kills CD20+ cells. FcγRIIIa-expressing cells are not killed.
Autologous T cells engineered with a chimeric antigen receptor to recognize and kill malignant B cells.
Autologous T cells are genetically engineered to express a chimeric antigen receptor that binds B-cell surface antigens (e.g., CD19) independent of HLA, activating T-cell signaling, proliferation, and cytotoxicity to eliminate malignant B cells via perforin/granzyme release and cytokine-mediated killing.
YES
DIRECT
CAR-T cells bind CD19 on target cells, trigger T-cell activation and immunologic synapse formation, then kill via perforin/granzyme-mediated apoptosis (with additional Fas/FasL and cytokine-mediated cytotoxicity).
Off-the-shelf allogeneic CAR NK cell therapy targeting GPC3 for advanced hepatocellular carcinoma; armed with calibrated-release IL-15 to support NK-cell survival, proliferation, and persistence.
Off-the-shelf allogeneic NK cells engineered with a CAR targeting glypican-3 (GPC3) recognize GPC3-expressing tumor cells and trigger NK-mediated cytotoxicity (perforin/granzyme and cytokine release). The product includes calibrated-release IL-15 to enhance NK-cell survival, proliferation, and persistence in vivo.
YES
DIRECT
CAR-engineered NK cells bind GPC3 on target cells and directly kill them via NK degranulation (perforin/granzyme–mediated cytotoxicity) and related apoptotic pathways; IL-15 supports NK survival/persistence.
Off-the-shelf allogeneic CAR NK cell therapy targeting GPC3 for advanced hepatocellular carcinoma; armed with calibrated-release IL-15 to support NK-cell survival, proliferation, and persistence.
Off-the-shelf allogeneic NK cells engineered with a CAR targeting glypican-3 (GPC3) recognize GPC3-expressing tumor cells and trigger NK-mediated cytotoxicity (perforin/granzyme and cytokine release). The product includes calibrated-release IL-15 to enhance NK-cell survival, proliferation, and persistence in vivo.
NO
INDIRECT
SN301A CAR-NK cells kill GPC3-expressing tumor cells via perforin/granzyme after CAR engagement. IL-15/IL-15Rα interactions support NK-cell survival/persistence and are not used to target IL-15Rα+ cells for killing.
Off-the-shelf allogeneic CAR NK cell therapy targeting GPC3 for advanced hepatocellular carcinoma; armed with calibrated-release IL-15 to support NK-cell survival, proliferation, and persistence.
Off-the-shelf allogeneic NK cells engineered with a CAR targeting glypican-3 (GPC3) recognize GPC3-expressing tumor cells and trigger NK-mediated cytotoxicity (perforin/granzyme and cytokine release). The product includes calibrated-release IL-15 to enhance NK-cell survival, proliferation, and persistence in vivo.
NO
INDIRECT
SN301A CAR-NK cells kill GPC3-positive tumor cells via perforin/granzyme after CAR engagement. CD122 (IL-2Rβ) is engaged by IL-15 to support NK-cell survival and proliferation, not as a cytotoxic target.